English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1785]
News [2810]
Articles [109]
Editorials [3]
Conferences [102]
elearning [7]
ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL
ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL
ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy
ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy
ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses in patients with heavily pretreated multiple myeloma
ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses...
ASH 2022: Novel drug shows early promise in treating multiple myeloma
ASH 2022: Novel drug shows early promise in treating multiple myeloma
ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in newly diagnosed, transplant-ineligible MM
ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in...
ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities
ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities
ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma
ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma
ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back
ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back
FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation
FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation
How AI found the words to kill cancer cells
How AI found the words to kill cancer cells
<1234567...281>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2023 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top